

Analysis of Availability and Access of Anti-myeloma Drugs and Impact on the Management of Multiple Myeloma in Latin American Countries

Pessoa de Magalhães Filho, Roberto José

Crusoe, Edvan

Riva, Eloisa

Bujan, Willen

Conte, Guilherme

Navarro Cabrera, Juan Ramon

Garcia, Diana Katerine

Vega, Guilherme Quintero

Macias, Jose

Oliveros Alvear, Jose Willian

Royg, Mercedes

Neves, Lidiane Andino

L

© 2018 Elsevier Inc. Latin American countries represents a large fraction of patients who are treated for multiple myeloma in the world and difficulties of access to new agents and real-world practice are important issues. In this study, we explore areas that impact the availability of anti-multiple myeloma drugs such as health care systems, approval times, coverage of new agents, old drugs, use of generics, and the first-line treatments in 16 nations. © 2018 Elsevier Inc. Introduction: Latin American countries (LATAMC) represent a large fraction of patients treated for multiple myeloma (MM) worldwide. In order to understand the difficulty of access to anti-myeloma therapy in LATAMC, we designed this study that explores areas involved in the availability of drugs, such as health care systems, approval times, coverage of new agents, old drugs, use of generics, and the first-line treatments. Material and Methods: We collected data from 16 countries in 2015. Results: The majority of LATAM